TELESIS BIO INC (TBIO) Stock Price, Quote, News and Overview
NASDAQ:TBIO - Nasdaq - US1920032000 - Common Stock - Currency: USD
TBIO Quote, Performance and Key Statistics
3.23
-0.76 (-19.05%)
The current stock price of TBIO is 3.23 USD. In the past month the price decreased by -3.87%. In the past year, price decreased by -82.75%.
TBIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About TBIO
Company Profile
Telesis Bio Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2021-06-18. Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The firm provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
Company Info
TELESIS BIO INC
10431 Wateridge Circle, Suite 150
San Diego CALIFORNIA 02421 US
CEO: Ronald C. Renaud Jr.
Employees: 137
Company Website: https://telesisbio.com/
Phone: 18582284115
TELESIS BIO INC / TBIO FAQ
What is the stock price of TELESIS BIO INC today?
The current stock price of TBIO is 3.23 USD. The price decreased by -19.05% in the last trading session.
What is the ticker symbol for TELESIS BIO INC stock?
The exchange symbol of TELESIS BIO INC is TBIO and it is listed on the Nasdaq exchange.
On which exchange is TBIO stock listed?
TBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TELESIS BIO INC stock?
7 analysts have analysed TBIO and the average price target is 4.08 USD. This implies a price increase of 26.32% is expected in the next year compared to the current price of 3.23. Check the TELESIS BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TELESIS BIO INC worth?
TELESIS BIO INC (TBIO) has a market capitalization of 5.72M USD. This makes TBIO a Nano Cap stock.
How many employees does TELESIS BIO INC have?
TELESIS BIO INC (TBIO) currently has 137 employees.
What are the support and resistance levels for TELESIS BIO INC (TBIO) stock?
TELESIS BIO INC (TBIO) has a resistance level at 4.07. Check the full technical report for a detailed analysis of TBIO support and resistance levels.
Is TELESIS BIO INC (TBIO) expected to grow?
The Revenue of TELESIS BIO INC (TBIO) is expected to decline by -66.55% in the next year. Check the estimates tab for more information on the TBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TELESIS BIO INC (TBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TBIO, evaluating the profitability, health, valuation and growth aspects
- TELESIS BIO INC (TBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TELESIS BIO INC (TBIO) Sales and EPS estimates to see what analysts future expectations are.
- TELESIS BIO INC (TBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TELESIS BIO INC (TBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- TELESIS BIO INC (TBIO) Stock Chart to make your own analysis
- TELESIS BIO INC (TBIO) Latest news and press-releases to stay up to date.
Does TELESIS BIO INC (TBIO) stock pay dividends?
TBIO does not pay a dividend.
When does TELESIS BIO INC (TBIO) report earnings?
TELESIS BIO INC (TBIO) will report earnings on 2024-11-11, after the market close.
What is the Price/Earnings (PE) ratio of TELESIS BIO INC (TBIO)?
TELESIS BIO INC (TBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-23.94).
What is the Short Interest ratio of TELESIS BIO INC (TBIO) stock?
The outstanding short interest for TELESIS BIO INC (TBIO) is 0.03% of its float. Check the ownership tab for more information on the TBIO short interest.
TBIO Technical Analysis
TBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TBIO. TBIO may be in some trouble as it scores bad on both profitability and health.
TBIO Financial Highlights
Over the last trailing twelve months TBIO reported a non-GAAP Earnings per Share(EPS) of -23.94. The EPS decreased by -1673.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.37% | ||
| ROE | -521.49% | ||
| Debt/Equity | 0.54 |
TBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TBIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -122.26% and a revenue growth -66.55% for TBIO